Skip to content

Effectivnes of edaravone on ischemic stroke

Evaluation of the effect of edaravone on the patients with ischemic stroke

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20240224061102N1
Enrollment
60
Registered
2024-05-11
Start date
2024-05-30
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke. Cerebral infarction

Interventions

Intervention 1: Intervention group: edaravone drug, 30 mg of the drug dissolved in 100 mg of normal saline for 60 minutes, will receive twice a day by injection for 10 days. Intervention 2: Control gr

Sponsors

Yasouj University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Participants with ischemic stroke based on clinical symptoms and CT scan Participants with ischemic stroke and NIHSS score of 16

Exclusion criteria

Exclusion criteria: Unwillingness to participate Significant cognitive and neurological impairments Presence of hemorrhagic stroke

Design outcomes

Primary

MeasureTime frame
Ischemic Severity. Timepoint: First and 10 days after intervention. Method of measurement: CT scan.;Radiological improvement rate. Timepoint: First and 10 days after intervention. Method of measurement: CT scan.;Rate of clinical improvement. Timepoint: First and 10 days after intervention. Method of measurement: NIHSS Scoring.;The level of consciousness of the patient. Timepoint: First and 10 days after intervention. Method of measurement: GCS scoring system.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaeid Razmeh

Yasouj University of Medical Sciences

srazmeh@yahoo.com+98 74 3226 9380

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026